Clinical and Translational Discovery · Published 2026-08-01 · DOI 10.1002/ctd2.70186
Qin Ouyang, Ke Gao, Haojie Lu, Shu Zhang
Abstract Metabolic reprogramming and glycosylation remodelling are hallmarks of cancer, and selected monosaccharides are increasingly recognized as key regulators of both processes. Beyond serving as fuels, glucose, galactose, mannose and fructose shape glycosylation, lipid synthesis, antitumour immunity and tumour–host communication. Here, we discuss how these monosaccharides are rerouted across tumour, immune and stromal compartments to generate context‐dependent tumour‐promoting or antitumour effects. We further evaluate pharmacological opportunities, including metabolic intervention, glycosylation‐directed therapy and rational combination strategies, while highlighting major translational barriers such as tumour heterogeneity, biomarker selection and systemic toxicity. This framework positions monosaccharide metabolism as a potential entry point for precision oncology.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →
Ouyang, Q., Gao, K., Lu, H., et al. (2026). Selected monosaccharides in cancer: Metabolic routing, post‐translational modification, immunity and therapeutic potential. Clinical and Translational Discovery. https://doi.org/10.1002/ctd2.70186